Elodie Odore

482 total citations
11 papers, 365 citations indexed

About

Elodie Odore is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Elodie Odore has authored 11 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Hematology and 2 papers in Genetics. Recurrent topics in Elodie Odore's work include Protein Degradation and Inhibitors (10 papers), Multiple Myeloma Research and Treatments (8 papers) and Histone Deacetylase Inhibitors Research (3 papers). Elodie Odore is often cited by papers focused on Protein Degradation and Inhibitors (10 papers), Multiple Myeloma Research and Treatments (8 papers) and Histone Deacetylase Inhibitors Research (3 papers). Elodie Odore collaborates with scholars based in France, Switzerland and Italy. Elodie Odore's co-authors include Esteban Cvitkovic, Keyvan Rezaï, Mohamed Békradda, María E. Riveiro, Lucile Astorgues‐Xerri, François Lokiec, Kay Noel, Francesco Bertoni, Sarah Mackenzie and L’Houcine Ouafik and has published in prestigious journals such as Cancer Research, International Journal of Cancer and European Journal of Cancer.

In The Last Decade

Elodie Odore

11 papers receiving 363 citations

Peers

Elodie Odore
Jean‐Richard Saint‐Martin United States
Londa Fuller United States
Veronica Guerra United States
Montserrat Pérez-Salvia Spain
Fieke W. Hoff United States
Xavier Thomas France
Christine Greil Germany
Evžen Gregora Czechia
Stephen S.Y. Lam Hong Kong
Shaoyi Li United States
Jean‐Richard Saint‐Martin United States
Elodie Odore
Citations per year, relative to Elodie Odore Elodie Odore (= 1×) peers Jean‐Richard Saint‐Martin

Countries citing papers authored by Elodie Odore

Since Specialization
Citations

This map shows the geographic impact of Elodie Odore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elodie Odore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elodie Odore more than expected).

Fields of papers citing papers by Elodie Odore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elodie Odore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elodie Odore. The network helps show where Elodie Odore may publish in the future.

Co-authorship network of co-authors of Elodie Odore

This figure shows the co-authorship network connecting the top 25 collaborators of Elodie Odore. A scholar is included among the top collaborators of Elodie Odore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elodie Odore. Elodie Odore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Odore, Elodie, et al.. (2018). Synthesis, characterization and solubility of mixed zirconium-cerium molybdate precipitates. Journal of Nuclear Science and Technology. 55(11). 1235–1244. 4 indexed citations
2.
Astorgues‐Xerri, Lucile, Elodie Odore, Esteban Cvitkovic, et al.. (2016). OTX015 (MK‐8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. International Journal of Cancer. 139(9). 2047–2055. 122 indexed citations
3.
Riveiro, María E., Lucile Astorgues‐Xerri, Ramiro Vázquez, et al.. (2016). OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget. 7(51). 84675–84687. 48 indexed citations
4.
Vázquez, Ramiro, María E. Riveiro, Lucile Astorgues‐Xerri, et al.. (2016). The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget. 8(5). 7598–7613. 81 indexed citations
5.
Gaudio, Eugenio, Chiara Tarantelli, Maurilio Ponzoni, et al.. (2016). Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strongin vivoantitumor activity in lymphoma. Oncotarget. 7(36). 58142–58147. 22 indexed citations
6.
Odore, Elodie, François Lokiec, Esteban Cvitkovic, et al.. (2015). Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. Clinical Pharmacokinetics. 55(3). 397–405. 72 indexed citations
7.
Odore, Elodie, François Lokiec, María E. Riveiro, et al.. (2015). Abstract 4511: Pharmacokinetics of OTX015 in a phase Ib dose-finding study of patients with hematologic malignancies: Preliminary results of a population PK analysis. Cancer Research. 75(15_Supplement). 4511–4511. 2 indexed citations
8.
Odore, Elodie, Keyvan Rezaï, Patrice Herait, et al.. (2014). Abstract LB-231: A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies. Cancer Research. 74(19_Supplement). LB–231. 2 indexed citations
9.
Odore, Elodie, François Lokiec, Patrice Herait, et al.. (2014). Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples. Analytical Methods. 6(22). 9108–9115. 8 indexed citations
10.
Astorgues‐Xerri, Lucile, et al.. (2014). 565 Preclinical evaluation of OTX015, a novel BET-BRD inhibitor, on small cell lung cancer (SCLC) cell lines. European Journal of Cancer. 50. 183–183. 2 indexed citations
11.
Odore, Elodie, Lucile Astorgues‐Xerri, Esteban Cvitkovic, et al.. (2014). 587 Cellular pharmacokinetics and molecular pharmacodynamics studies of the BRD-BET inhibitor OTX015 in sensitive and resistant leukemic cell lines. European Journal of Cancer. 50. 189–189. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean‐Richard Saint‐Martin Breakdown of academic impact, for papers by Londa Fuller Breakdown of academic impact, for papers by Veronica Guerra Breakdown of academic impact, for papers by Montserrat Pérez-Salvia Breakdown of academic impact, for papers by Fieke W. Hoff Breakdown of academic impact, for papers by Xavier Thomas Breakdown of academic impact, for papers by Christine Greil Breakdown of academic impact, for papers by Evžen Gregora Breakdown of academic impact, for papers by Stephen S.Y. Lam Breakdown of academic impact, for papers by Shaoyi Li
Rankless by CCL
2026